Skip to main content

Table 1 Discounted life-years, QALYs and incremental cost-effectiveness ratios of chemotherapy in the Austrian setting versus Canadian setting

From: Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

 

Austrian setting

Canadian setting

Risk category

Chemo

LYs

QALYs

Costs (€)

ICER (€/QALY)

LYs

QALYs

Costs (€)

ICER (€/QALY)

AO

ODX

Low

Low

No

15.51

12.04

11,021

D

15.36

11.93

10,088

D

Yes

15.16

11.65

23,383

15.14

11.69

11,817

Low

Int.

No

14.96

11.61

12,063

D

14.85

11.52

11,279

61,861

Yes

15.05

11.57

23,608

15.04

11.61

16,562

Low

High

No

12.06

9.31

17,520

3361

12.07

9.32

17,368

3118

Yes

14.73

11.31

24,240

14.73

11.37

23,743

Low

N/A

No

14.80

11.48

9230

566,277

14.69

11.40

8347

3768

Yes

14.97

11.50

20,554

14.96

11.55

8925

Int.

Low

No

15.21

11.80

11,557

D

15.10

11.72

10,708

D

Yes

15.02

11.54

23,641

15.01

11.59

12,105

Int.

Int.

No

13.71

10.62

14,421

13,504

13.69

10.60

13,872

4094

Yes

14.77

11.34

24,163

14.78

11.40

17,150

Int.

High

No

9.45

7.25

21,733

698

9.51

7.30

22,401

416

Yes

14.61

11.21

24,500

14.60

11.26

24,049

Int.

N/A

No

12.63

9.77

13,372

4790

12.63

9.76

12,927

548

Yes

14.78

11.35

20,960

14.79

11.41

13,833

High

Low

No

15.21

11.81

11,561

D

15.09

11.71

10,721

D

Yes

15.03

11.55

23,666

15.01

11.59

12,116

High

Int.

No

13.76

10.66

14,471

14,496

13.66

10.58

13,969

3940

Yes

14.75

11.33

24,143

14.77

11.40

17,186

High

High

No

9.43

7.23

21,815

676

9.48

7.27

22,474

400

Yes

14.60

11.21

24,502

14.59

11.26

24,068

High

N/A

No

12.09

9.34

14,257

3097

12.08

9.33

14,078

2816

Yes

14.88

11.43

20,729

14.87

11.48

20,121

  1. Abbreviations: AO Adjuvant!Online, ODX OncotypeDX, Int. Intermediate, LYs life years, QALYs quality-adjusted life-years, ICER incremental cost-effectiveness ratio, N/A ODX test not applied
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us